Registered title, quoted from ClinicalTrials.gov
Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma
An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07744529, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 4
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (4 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Negative serum pregnancy test, and effective contraception from signing the informed consent form until 6 months after the last chemotherapy dose.
Inclusion criterion 11
Complete blood count: absolute neutrophil count (ANC) >=1.5 x 10\^9/L (1500/mm\^3), platelets >=75 x 10\^9/L, hemoglobin >=9 g/dL (if bone marrow is involved, platelets >=50 x 10\^9/L, ANC >=1.0 x 10\^9/L and hemoglobin >=8 g/dL).
Inclusion criterion 6
Liver function: serum bilirubin <=1.5 x upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=1.5 x ULN (if there is liver involvement, AST and ALT <=5 x ULN are allowed).
Inclusion criterion 7
Renal function: serum creatinine <=1.5 x ULN.
Inclusion criterion 8
Coagulation function: INR <=1.5 x ULN; PT and APTT <=1.5 x ULN (unless the subject is receiving anticoagulant therapy and PT and APTT are within the expected range of anticoagulant treatment at screening).
Inclusion criterion 9
History of other malignancies within the past 5 years.
Exclusion criterion 2
Patients with known history of human immunodeficiency virus (HIV) infection and/or acquired immunodeficiency syndrome.
Exclusion criterion 4
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07744529, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntary participation in the clinical study: fully understands and is informed of this study and signs the written informed consent form; is willing and able to complete all trial procedures.
- Age: >=18 years; male or female.
- Patients with EGFR-mutated lung adenocarcinoma with leptomeningeal metastasis diagnosed according to the EANO-ESMO guidelines.
- Expected survival of at least 3 months.
- Adequate organ and bone marrow function, with no severe hematopoietic abnormality and no severe cardiac, pulmonary, hepatic or renal dysfunction or immunodeficiency (within 14 days before use of study drug, no blood transfusion, granulocyte colony-stimulating factor or other relevant medical support):
- Complete blood count: absolute neutrophil count (ANC) >=1.5 x 10\^9/L (1500/mm\^3), platelets >=75 x 10\^9/L, hemoglobin >=9 g/dL (if bone marrow is involved, platelets >=50 x 10\^9/L, ANC >=1.0 x 10\^9/L and hemoglobin >=8 g/dL).
- Liver function: serum bilirubin <=1.5 x upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=1.5 x ULN (if there is liver involvement, AST and ALT <=5 x ULN are allowed).
- Renal function: serum creatinine <=1.5 x ULN.
- Coagulation function: INR <=1.5 x ULN; PT and APTT <=1.5 x ULN (unless the subject is receiving anticoagulant therapy and PT and APTT are within the expected range of anticoagulant treatment at screening).
- Left ventricular ejection fraction (LVEF) in cardiac function examination >=50%.
- Negative serum pregnancy test, and effective contraception from signing the informed consent form until 6 months after the last chemotherapy dose.
- Thyroid-stimulating hormone (TSH), free thyroxine (FT4) or free triiodothyronine (FT3) within +/-10% of the normal range.
- Ophthalmic examination, including dilated fundus examination, slit-lamp examination and color fundus photography.
Exclusion Criteria:
- Currently participating in another clinical study, or less than 4 weeks between the first dose of the study drug and the end of treatment in a previous clinical study.
- History of other malignancies within the past 5 years.
- Patients who have received CNS-directed prophylactic treatment.
- Patients with known history of human immunodeficiency virus (HIV) infection and/or acquired immunodeficiency syndrome.
- Patients with active autoimmune disease or a history of autoimmune disease with a high risk of recurrence, including but not limited to immune-related neuropathy, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis, systemic lupus erythematosus, connective tissue disease, scleroderma, inflammatory bowel cancer (including Crohn disease and ulcerative colitis), autoimmune hepatitis, toxic epidermal necrolysis or Stevens-Johnson syndrome.
- Patients with active chronic hepatitis B or active hepatitis C. Patients who are positive for hepatitis B surface antigen or hepatitis C virus antibody during screening may be enrolled only after further HBV DNA titer testing (not higher than 1000 IU/mL) and HCV RNA testing (not exceeding the lower limit of detection of the assay), and after active hepatitis B or hepatitis C infection requiring treatment has been excluded. Hepatitis B virus carriers, patients with stable hepatitis B after drug treatment and patients with cured hepatitis C may be enrolled.
- Active pulmonary tuberculosis.
- Current interstitial lung disease or infectious pneumonia.
- Active infection requiring systemic anti-infective therapy, including but not limited to bacterial, fungal or viral infection.
- Within 6 months before screening, New York Heart Association (NYHA) class III or IV heart failure, unstable angina, severe poorly controlled ventricular arrhythmia, or electrocardiographic evidence of acute ischemia or myocardial infarction.
- QTcF interval >480 msec, unless secondary to bundle branch block.
- Uncontrolled comorbid disease, including but not limited to uncontrolled hypertension, active peptic ulcer or bleeding disorder.
- History of psychiatric illness; incapacity or limited capacity for civil conduct.
- In the judgment of the investigator, the patient's underlying condition may increase the risk of receiving study drug treatment or confound the occurrence and assessment of toxic reactions.
- Other patients whom the investigator considers unsuitable for participation in this study.
Quoted from ClinicalTrials.gov, NCT07744529, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07744529, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.